

1H2024 Results Briefing

Tuesday, 3 September 2024



Management Panel



Mr. David Seow

Executive Director and

Group Chief Executive Officer



Mr. Jason Lim
Chief Operating Officer



Mr. Adriel Low

Deputy Chief Operating Officer



Ms. Daisy Ong
Chief Financial Officer

Agenda


- Financial Performance
- Business Updates
- Outlook
- Q&A






Financial Performance

1H2024 Snapshot





s\$**57.8**m

as at 30 Jun 2024

NET CASH POSTION

7.6¢

per ordinary share

NET CASH PER SHARE

18.4¢

per ordinary share

NAV

REVENUE

1H2024

s\$0.1m

net profit


1H2023

s\$3.9m

net loss

NET PROFIT/LOSS

1H2024 Review - Revenue





Manufacturing Revenue by Geography

S\$'M	1H2024	1H2023	Change (%)
Singapore	21.0	19.7	6.6
Malaysia	17.8	12.8	39.1
China	16.0	20.1	(20.4)

- Group-wide revenue rose 78.0%, propelled by higher sales for both manufacturing and supply chain management segments
- 1H2024 manufacturing revenue rose to S\$54.8M (1H2023: S\$52.6M)
- Higher sales in Singapore and Malaysia, partially offset by lower contributions from China
- Supply chain management services posted revenue of S\$72.0M (1H2023: S\$18.6M)


1H2024 Review - Gross and Net Profit





- 1H2024 gross profit rose 32.8% to S\$8.5M from S\$6.4M in 1H2023
- GPM for 1H2024 stood at 6.7% (1H2023: 9.0%) due to change in revenue mix
- Recorded net profit of S\$0.1M, reversal from S\$3.9 million net loss
- S\$0.8M operating profit in 1H2024 (1H2023: S\$3.8M operating loss)
- S\$0.6M net profit from supply chain management services (1H2023: S\$0.2M net loss) offsets S\$0.5M net loss in manufacturing business (1H2023: S\$3.7M net loss)

Yearly Financial Performance



Strong Financial Position

s\$**59.1**m

As of 30 Jun 2024

s\$60.3m

As of 31 Dec 2023

CASH AND BANK BALANCES

s\$180.1m

As of 30 Jun 2024

s\$176.2m

As of 31 Dec 2023

 Increase mainly attributed to the growth in trade and other receivables, inventories, and contract assets

Recorded CAPEX of S\$3.9 million mainly for purchase

S\$59.1M cash and bank balance; subtracting S\$1.3M

unsecured bank loans, net cash stands at S\$57.8M

of new machineries in Singapore

TOTAL ASSETS

s\$40.3m

As of 30 Jun 2024

s\$38.7m

As of 31 Dec 2023

Increase mainly due to higher trade and other payables

TOTAL LIABILITIES

9



Business Updates

Project Wins - myFirst

NEWS RELEASE

Singapore's Kids-Tech Startup myFirst Partners SGX-listed Fu Yu for Major Expansion to 20,000 Locations including North America

- · North American expansion plan will extend myFirst's global presence from 4,000 locations to over 20,000, including Walmart, Costco and Best Buy
- Expansion follows myFirst's Pre-Series A funding round from Lynx Asia Partners and angel investors
- · myFirst is well-positioned to meet the growing demand for social media safety through its kid-friendly social media ecosystem, watchphones, cameras, earbuds, 3D pens and headphones
- . Fu Yu will be myFirst's exclusive contract manufacturer, undertaking the manufacture and assembly of the latter's products, with the ability to scale up production to support myFirst's expansion plans
- Fu Yu will leverage state-of-the-art manufacturing technologies within its Smart Factory in Singapore, including rapid prototyping, metal 3D printing, liquid silicone rubber injection moulding, and automated high-precision tool fabrication



Fu Yu's Group CEO Mr David Seow, with myFirst's co-founder and CEO G-Jay Yong in front of myFirst's retail store at Suntec City

Page 1 of 4



THE BUSINESS TIMES

New Projects and Collaborations

New Project Wins

In 1H2024, Fu Yu secured project with an international biomedical company to produce microfluidic chips (used in medical diagnostic devices)

Signed partnership with a Contract Development and Manufacturing Organisation to produce high-precision tools used to manufacture drug delivery devices

Group signed an MoU in 1Q2024 to be the exclusive plastics supplier for a local medical device manufacturer; both parties will also collaborate to target MedTech companies

Conclusion & Outlook

Industry Outlook

Several headwinds could hamper pace of recovery: longer shipping lead times, higher costs of raw materials and further disruptions to the supply chain, arising from geopolitical tensions

US election run-up could further escalate US-China trade tensions; in response, Fu Yu's facilities in China are focused on China-for-China and China-for-Asia strategies

Group Outlook

Fu Yu recorded higher-order volumes and inquiries for new projects; business momentum expected to grow in 2H2024

Strategic initiatives to enhance manufacturing capabilities and expand customer base is bearing early fruits; Group will continue to execute its corporate strategies in the coming months



Q&A



MEDIA & INVESTOR CONTACT

Fu Yu Corporation Limited Contact: Daisy Ong, CFO <u>ir@fuyucorp.com</u> WeR1 Consultants Pte Ltd Tel: (65) 6721 7161

Isaac Tang: fuyu@wer1.net